Notice of Meeting; Correction, 80323-80324 [2023-25463]

Download as PDF Federal Register / Vol. 88, No. 221 / Friday, November 17, 2023 / Notices Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W104, Rockville, Maryland 20850, 240–276–6351, david.ransom@nih.gov. Name of Committee: National Cancer Institute Initial Review Group, Transition to Independence Study Section (I). Date: February 15–16, 2024. Time: 11:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W602 Rockville, Maryland 20850, (Virtual Meeting). Contact Person: Delia Tang, M.D., Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W602, Rockville, Maryland 20850, 240–276–6456. tangd@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel, SEP–10: NCI Clinical and Translational Cancer Research. Date: February 22–23, 2024. Time: 10:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W606, Rockville, Maryland 20850, (Virtual Meeting). Contact Person: Bruce Daniel Hissong, Ph.D., Scientific Review Officer, Resource and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W606 Rockville, Maryland 20850, 240–276–7752. bruce.hissong@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: November 14, 2023. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2023–25490 Filed 11–16–23; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES khammond on DSKJM1Z7X2PROD with NOTICES Substance Abuse and Mental Health Services Administration Notice of Meeting; Correction Substance Abuse and Mental Health Services Administration, HHS. ACTION: Notice; correction. AGENCY: The Substance Abuse and Mental Health Services Administration SUMMARY: VerDate Sep<11>2014 18:57 Nov 16, 2023 Jkt 262001 (SAMHSA) published a document in the Federal Register of October 17, 2023, in FR Doc. 2023–22797 announcing the meeting of the SAMHSA Center for Substance Abuse Prevention (CSAP) Drug Testing Advisory Board (DTAB) on December 5, 2023, and to request comments on editing the Authorized Drug Testing Panels for federally regulated testing. The document was revised to reflect new information under the Supplementary Section. FOR FURTHER INFORMATION CONTACT: Lisa Davis, Division of Workplace Programs, SAMHSA/CSAP, 5600 Fishers Lane, Rockville, MD 20857, (240) 276–1440 (voice), Lisa.Davis@samhsa.hhs.gov (email). SUPPLEMENTARY INFORMATION: Notice of Meeting Pursuant to Public Law 92–463, notice is hereby given that the Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center for Substance Abuse Prevention’s (CSAP) Drug Testing Advisory Board (DTAB) will convene via web conference on December 5, 2023, from 10:00 a.m. EST to 4:30 p.m. The board will meet in open-session December 5, 2023, from 10:00 a.m. EST to 4:30 p.m. EST to hear Federal Partner updates and presentations regarding National Laboratory Certification Program (NLCP) activities, updates to the Medical Review Officer (MRO) Guidance Manual, laboratory-created cannabinoids and other contaminants in commercially available products, and the process for adding or removing analytes from the Authorized Drug Testing Panels for federally regulated testing. The Board will discuss the Mandatory Guidelines for Federal Workplace Drug Testing Programs and revisions to the Authorized Drug Testing Panels for Urine and Oral Fluid to add fentanyl and (for urine) norfentanyl, and to remove methylenedioxymethamphetamine (MDMA) and methylenedioxyamphetamine (MDA). Additionally, the Department is asking for public comments on these recommended changes to the drug testing panel. Section 8105 of the Fighting Opioid Abuse in Transportation Act, included in the SUPPORT for Patients and Communities Act, required the Secretary to determine whether it is justified, based on the reliability and cost-effectiveness of testing, to revise the Mandatory Guidelines for Federal Workplace Drug Testing Programs to include fentanyl. Section 8105 additionally required the Secretary to PO 00000 Frm 00055 Fmt 4703 Sfmt 4703 80323 consider whether to include any other drugs or other substances listed in Schedule I and II of Controlled Substances Act (CSA). Norfentanyl is a metabolite of fentanyl. Because it is also an immediate precursor used in the illicit manufacture of fentanyl, it is a Schedule II substance under the CSA. Fentanyl accounts for a large proportion of overdose deaths in the United States and is therefore an important public safety concern. Furthermore, fentanyl is increasingly used as a stand-alone substance of abuse, not in conjunction with heroin and other substances. According to the National Forensic Laboratory Information System (NFLIS) 2021 report, fentanyl was the 4th most frequently identified drug and accounted for 11.61% of all drugs reported by forensic laboratories.1 Norfentanyl is an important component of identifying fentanyl users when urine is the specimen matrix. Fentanyl has been detected in oral fluid in pain management patients, overdose cases, and driving under the influence of drugs (DUID) cases. Information provided by HHS-certified laboratories in 2023 indicated that a majority (84%) of the laboratories analyzed non-regulated workplace specimens for fentanyl and/ or norfentanyl, and that all had the ability to analyze urine specimens for fentanyl with sufficiently sensitive detection limits using commercially available immunoassay kits and confirmatory test instrumentation commonly used in HHS-certified laboratories. The Division of Workplace Programs welcomes public comment prior to the DTAB meeting regarding the possible addition of fentanyl to the Authorized Drug Testing Panels for Urine and Oral Fluid. Please see below for the process to submit comments. Addition to HHS Drug Testing Panels as listed below: Urine analyte Initial test cutoff Fentanyl ............ Norfentanyl ....... 1 ng/mL ...... 1 ng/mL ...... Oral fluid analyte Initial test cutoff Fentanyl ............ 1 ng/mL ...... Confirmation cutoff 0.5 ng/mL. 0.5 ng/mL. Confirmation cutoff 0.5 ng/mL. Remove Methylenedioxyamphetamine (MDA) and Methylenedioxymethamphetamine (MDMA) from the Authorized Drug Testing Panel: The Department plans to remove MDA and E:\FR\FM\17NON1.SGM 17NON1 khammond on DSKJM1Z7X2PROD with NOTICES 80324 Federal Register / Vol. 88, No. 221 / Friday, November 17, 2023 / Notices methylenedioxymethamphetamine from the drug testing panel, because the number of positive specimens reported by HHS-certified laboratories does not support testing all specimens for MDA and MDMA in Federal workplace drug testing programs. Information provided to the Department through the NLCP in 2021 and 2022 shows the positivity rate for MDMA ranges from 0.001 to 0.003%, and a review of the results indicate that >25% of the positive specimens are likely agency blind samples. MDA has a lower positivity rate than MDMA and both have lower positivity rates than phencyclidine (PCP). SAMHSA also considered removing PCP but decided against this change. While PCP has an overall positivity rate nearly as low as MDMA, there are regional differences in positivity, with some areas of the country having much higher rates, so PCP remains a regulated test analyte. Because MDA and MDMA are Schedule I drugs, a Federal agency may test specimens for these analytes in accordance with Section 3.2 of the UrMG and OFMG (i.e., on a case-by-case basis for reasonable suspicion or postaccident testing, or routinely with a waiver from the Secretary). The Division of Workplace Programs welcomes public comment prior to the DTAB meeting regarding the removal of MDA and MDMA from the Urine and Oral Fluid Analyte Table. Please see below for the process to submit comments. Meeting registration information can be completed at https://snacregister. samhsa.gov/. Web conference and call information will be sent after completing registration. Meeting information and a roster of DTAB members may be obtained by accessing the SAMHSA Advisory Committees website, https://www.samhsa.gov/ about-us/advisory-councils/meetings, or by contacting the Designated Federal Officer, Lisa Davis. Committee Name: Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Prevention, Drug Testing Advisory Board. Dates/Time/Type: December 5, 2023, from 10:00 a.m. EST to 4:30 p.m. EST: OPEN Place: Virtual. To Submit Comments: Requests to make public comment during the public comment period of the December DTAB meeting must be made in writing at least 7 days prior to the meeting to the following email: DFWP@ samhsa.hhs.gov. Please submit written comments regarding the addition of Fentanyl and the removal of MDA and MDMA to the VerDate Sep<11>2014 18:57 Nov 16, 2023 Jkt 262001 analyte table to the following email: DFWP@samhsa.hhs.gov. Comments regarding the addition of Fentanyl and the removal of MDA and MDMA to the analyte table will be accepted for review for an additional 30 days following this meeting, or no later than January 4th, 2024. Contact: Lisa S. Davis, M.S., Social Science Analyst, Center for Substance Abuse Prevention, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone: (240) 276–1440, email: Lisa.Davis@ samhsa.hhs.gov. Endnote: 1 National Forensic Laboratory Information System (NFLIS). (2021). NFLIS-Drug 2021 Annual Report. U.S. Department of Justice, Drug Enforcement Agency, Diversion Control Division. https://www.nflis.deadiversion. usdoj.gov/. Dated: November 13, 2023. Anastasia Flanagan, Public Health Advisor, Division of Workplace Programs. [FR Doc. 2023–25463 Filed 11–16–23; 8:45 am] BILLING CODE 4162–20–P DEPARTMENT OF HOMELAND SECURITY Federal Emergency Management Agency [Docket ID: FEMA–2023–0030; OMB No. 1660–0125] Agency Information Collection Activities: Proposed Collection; Comment Request; FEMA Preparedness Grants: Homeland Security Grant Program (HSGP) Federal Emergency Management Agency, Department of Homeland Security. ACTION: 60-Day notice of revision and request for comments. AGENCY: The Federal Emergency Management Agency (FEMA), as part of its continuing effort to reduce paperwork and respondent burden, invites the general public to take this opportunity to comment on a revision of a currently approved information collection. In accordance with the Paperwork Reduction Act of 1995, this notice seeks comments concerning the Homeland Security Grant Program (HSGP), which includes the State Homeland Security Program (SHSP), the Urban Area Security Initiative (UASI), and Operation Stonegarden (OPSG). This revision removes the OPSG Daily Activity Report (FEMA Form FF–207– FY–21–113 (formerly 089–0–27)) from the collection. SUMMARY: PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 Comments must be submitted on or before January 16, 2024. ADDRESSES: To avoid duplicate submissions to the docket, please submit comments at www.regulations.gov under Docket ID FEMA–2023–0030. Follow the instructions for submitting comments. All submissions received must include the agency name and Docket ID. Regardless of the method used for submitting comments or material, all submissions will be posted, without change, to the Federal eRulemaking Portal at https://www.regulations.gov, and will include any personal information you provide. Therefore, submitting this information makes it public. You may wish to read the Privacy and Security Notice that is available via a link on the homepage of www.regulations.gov. FOR FURTHER INFORMATION CONTACT: Alexander Mrazik Jr., Branch Chief, FEMA’s Grant Programs Directorate, Grant Operations Division, Preparedness Grants Division, Homeland Security Programs Branch, at (202) 786–9732 or Alexander.MrazikJr@ fema.dhs.gov. You may contact the Information Management Division for copies of the proposed collection of information at email address: FEMAInformation-Collections-Management@ fema.dhs.gov. SUPPLEMENTARY INFORMATION: The Federal Emergency Management Agency’s (FEMA’s) Homeland Security Grant Program (HSGP) supports state and local efforts to prevent terrorism and other catastrophic events and to prepare the Nation for the threats and hazards that pose the greatest risk to the security of the United States. The HSGP provides funding to implement investments that build, sustain, and deliver the 32 core capabilities essential to achieving the National Preparedness Goal of a secure and resilient Nation. The building, sustainment, and delivery of these core capabilities are not exclusive to any single level of government, organization, or community, but rather, require the combined effort of the whole community. The HSGP supports core capabilities across the five mission areas of Prevention, Protection, Mitigation, Response, and Recovery based on allowable costs. HSGP is comprised of three grant programs: State Homeland Security Program (SHSP), Urban Area Security Initiative (UASI), and Operation Stonegarden (OPSG). Together, these grant programs fund a range of activities, including planning, organization, equipment purchase, training, exercises, and management DATES: E:\FR\FM\17NON1.SGM 17NON1

Agencies

[Federal Register Volume 88, Number 221 (Friday, November 17, 2023)]
[Notices]
[Pages 80323-80324]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-25463]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration


Notice of Meeting; Correction

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice; correction.

-----------------------------------------------------------------------

SUMMARY: The Substance Abuse and Mental Health Services Administration 
(SAMHSA) published a document in the Federal Register of October 17, 
2023, in FR Doc. 2023-22797 announcing the meeting of the SAMHSA Center 
for Substance Abuse Prevention (CSAP) Drug Testing Advisory Board 
(DTAB) on December 5, 2023, and to request comments on editing the 
Authorized Drug Testing Panels for federally regulated testing. The 
document was revised to reflect new information under the Supplementary 
Section.

FOR FURTHER INFORMATION CONTACT: Lisa Davis, Division of Workplace 
Programs, SAMHSA/CSAP, 5600 Fishers Lane, Rockville, MD 20857, (240) 
276-1440 (voice), [email protected] (email).

SUPPLEMENTARY INFORMATION:

Notice of Meeting

    Pursuant to Public Law 92-463, notice is hereby given that the 
Substance Abuse and Mental Health Services Administration's (SAMHSA) 
Center for Substance Abuse Prevention's (CSAP) Drug Testing Advisory 
Board (DTAB) will convene via web conference on December 5, 2023, from 
10:00 a.m. EST to 4:30 p.m.
    The board will meet in open-session December 5, 2023, from 10:00 
a.m. EST to 4:30 p.m. EST to hear Federal Partner updates and 
presentations regarding National Laboratory Certification Program 
(NLCP) activities, updates to the Medical Review Officer (MRO) Guidance 
Manual, laboratory-created cannabinoids and other contaminants in 
commercially available products, and the process for adding or removing 
analytes from the Authorized Drug Testing Panels for federally 
regulated testing. The Board will discuss the Mandatory Guidelines for 
Federal Workplace Drug Testing Programs and revisions to the Authorized 
Drug Testing Panels for Urine and Oral Fluid to add fentanyl and (for 
urine) nor-fentanyl, and to remove methylenedioxymethamphetamine (MDMA) 
and methylenedioxyamphetamine (MDA). Additionally, the Department is 
asking for public comments on these recommended changes to the drug 
testing panel.
    Section 8105 of the Fighting Opioid Abuse in Transportation Act, 
included in the SUPPORT for Patients and Communities Act, required the 
Secretary to determine whether it is justified, based on the 
reliability and cost-effectiveness of testing, to revise the Mandatory 
Guidelines for Federal Workplace Drug Testing Programs to include 
fentanyl. Section 8105 additionally required the Secretary to consider 
whether to include any other drugs or other substances listed in 
Schedule I and II of Controlled Substances Act (CSA). Norfentanyl is a 
metabolite of fentanyl. Because it is also an immediate precursor used 
in the illicit manufacture of fentanyl, it is a Schedule II substance 
under the CSA.
    Fentanyl accounts for a large proportion of overdose deaths in the 
United States and is therefore an important public safety concern. 
Furthermore, fentanyl is increasingly used as a stand-alone substance 
of abuse, not in conjunction with heroin and other substances. 
According to the National Forensic Laboratory Information System 
(NFLIS) 2021 report, fentanyl was the 4th most frequently identified 
drug and accounted for 11.61% of all drugs reported by forensic 
laboratories.\1\ Norfentanyl is an important component of identifying 
fentanyl users when urine is the specimen matrix. Fentanyl has been 
detected in oral fluid in pain management patients, overdose cases, and 
driving under the influence of drugs (DUID) cases. Information provided 
by HHS-certified laboratories in 2023 indicated that a majority (84%) 
of the laboratories analyzed non-regulated workplace specimens for 
fentanyl and/or norfentanyl, and that all had the ability to analyze 
urine specimens for fentanyl with sufficiently sensitive detection 
limits using commercially available immunoassay kits and confirmatory 
test instrumentation commonly used in HHS-certified laboratories.
    The Division of Workplace Programs welcomes public comment prior to 
the DTAB meeting regarding the possible addition of fentanyl to the 
Authorized Drug Testing Panels for Urine and Oral Fluid. Please see 
below for the process to submit comments.
    Addition to HHS Drug Testing Panels as listed below:

------------------------------------------------------------------------
                                     Initial test        Confirmation
          Urine analyte                 cutoff              cutoff
------------------------------------------------------------------------
Fentanyl........................  1 ng/mL...........  0.5 ng/mL.
Norfentanyl.....................  1 ng/mL...........  0.5 ng/mL.
------------------------------------------------------------------------


------------------------------------------------------------------------
                                     Initial test        Confirmation
       Oral fluid analyte               cutoff              cutoff
------------------------------------------------------------------------
Fentanyl........................  1 ng/mL...........  0.5 ng/mL.
------------------------------------------------------------------------

    Remove Methylenedioxyamphetamine (MDA) and 
Methylenedioxymethamphetamine (MDMA) from the Authorized Drug Testing 
Panel:
    The Department plans to remove MDA and

[[Page 80324]]

methylenedioxymethamphetamine from the drug testing panel, because the 
number of positive specimens reported by HHS-certified laboratories 
does not support testing all specimens for MDA and MDMA in Federal 
workplace drug testing programs. Information provided to the Department 
through the NLCP in 2021 and 2022 shows the positivity rate for MDMA 
ranges from 0.001 to 0.003%, and a review of the results indicate that 
>25% of the positive specimens are likely agency blind samples. MDA has 
a lower positivity rate than MDMA and both have lower positivity rates 
than phencyclidine (PCP). SAMHSA also considered removing PCP but 
decided against this change. While PCP has an overall positivity rate 
nearly as low as MDMA, there are regional differences in positivity, 
with some areas of the country having much higher rates, so PCP remains 
a regulated test analyte. Because MDA and MDMA are Schedule I drugs, a 
Federal agency may test specimens for these analytes in accordance with 
Section 3.2 of the UrMG and OFMG (i.e., on a case-by-case basis for 
reasonable suspicion or post-accident testing, or routinely with a 
waiver from the Secretary). The Division of Workplace Programs welcomes 
public comment prior to the DTAB meeting regarding the removal of MDA 
and MDMA from the Urine and Oral Fluid Analyte Table. Please see below 
for the process to submit comments.
    Meeting registration information can be completed at https://snacregister.samhsa.gov/. Web conference and call information will be 
sent after completing registration. Meeting information and a roster of 
DTAB members may be obtained by accessing the SAMHSA Advisory 
Committees website, https://www.samhsa.gov/about-us/advisory-councils/meetings, or by contacting the Designated Federal Officer, Lisa Davis.
    Committee Name: Substance Abuse and Mental Health Services 
Administration, Center for Substance Abuse Prevention, Drug Testing 
Advisory Board.
    Dates/Time/Type: December 5, 2023, from 10:00 a.m. EST to 4:30 p.m. 
EST: OPEN
    Place: Virtual.
    To Submit Comments: Requests to make public comment during the 
public comment period of the December DTAB meeting must be made in 
writing at least 7 days prior to the meeting to the following email: 
[email protected].
    Please submit written comments regarding the addition of Fentanyl 
and the removal of MDA and MDMA to the analyte table to the following 
email: [email protected].
    Comments regarding the addition of Fentanyl and the removal of MDA 
and MDMA to the analyte table will be accepted for review for an 
additional 30 days following this meeting, or no later than January 
4th, 2024.
    Contact: Lisa S. Davis, M.S., Social Science Analyst, Center for 
Substance Abuse Prevention, 5600 Fishers Lane, Rockville, Maryland 
20857, Telephone: (240) 276-1440, email: [email protected].

Endnote:

    \1\ National Forensic Laboratory Information System (NFLIS). 
(2021). NFLIS-Drug 2021 Annual Report. U.S. Department of Justice, 
Drug Enforcement Agency, Diversion Control Division. https://www.nflis.deadiversion.usdoj.gov/.

    Dated: November 13, 2023.
Anastasia Flanagan,
Public Health Advisor, Division of Workplace Programs.
[FR Doc. 2023-25463 Filed 11-16-23; 8:45 am]
BILLING CODE 4162-20-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.